Digital biomarkers are defined as objective, quantifiable physiological & behavioral data collected and measured through digital devices such as portables, wearables, implantables, and/or digestible. The data collected by these digital devices is typically used to explain, influence, or predict health-related outcomes. Thus, the demand for digital biomarkers is increasing with a rapid pace.
Growing prevalence of chronic diseases, rising adoption of digital healthcare solutions, increasing research and development, growing adoption of patient-centric healthcare applications, rising use of smartphones, emergence of novel wearables, and expanding therapeutic applications are major factors expected to drive growth of the global digital biomarkersmarket.
For instance, in February 2023, Ad Scientiam announced the launch of two ambitious programs to develop and validate digital biomarkers for self-assessment of patients suffering from generalized myasthenia gravis (gMG) and neuromyelitis optica spectrum disorders (NMOSD). The programs will leverage assets, methodologies, and expertise built by Ad Scientiam over the past five years and are supported by Alexion, AstraZeneca Rare Disease.
- This report provides in-depth analysis of the global digital biomarkersmarket, and provides market size (US$ Billion) and compound annual growth rate (CAGR%) for the forecast period 2026-2033, considering 2025 as the base year.
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
- It profiles key players in the global digital biomarkersmarket based on the following parameters such as company highlights, products portfolio, key highlights, financial performance, and strategies.
- Key companies covered as a part of this study include AliveCor Inc., Altoida Inc., Amgen Inc., Human API, Fitbit, Inc., Biogen Inc, Bayer AG, Akili Interactive Labs, Evidation Health, Inc., GlaxoSmithKline Plc, and Eli Lilly and Company, among others.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
- The global digital biomarkersmarket report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global digital biomarkersmarket.
-
- Wearable Devices
- Implantable Components/Sensors
- Mobile/Tablet Apps
- Platforms
- Desktop Based Software
- Data Integration (Systems that Integrate Data)
-
- Sleep and Movement
- Cardiovascular Disease
- Mood and Behavior
- Pain Management
- Neurodegenerative Disorders
- Respiratory Conditions
-
- Biopharmaceutical Companies
- Providers
- Payers
-
- North America
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
-
- AliveCor Inc.
- Altoida Inc.
- Amgen Inc.
- Human API
- Fitbit, Inc.
- Biogen Inc.
- Bayer AG
- Akili Interactive Labs
- Evidation Health, Inc.
- GlaxoSmithKline Plc
- Eli Lilly and Company
